The MedicX Fund Limited
15 April 2008
For immediate release 15 April 2008
MedicX Fund Limited
('MedicX Fund', 'the Fund' or 'the Company')
Completion of Warwick Medical Centre
MedicX Fund, (LSE: MXF), the specialist investor in modern purpose built primary
healthcare properties, today announces that it has completed the development of
its Warwick Medical Centre. The acquisition price is £2.115 million and the
aggregate rent of the property is £125,975 per annum. This is the fourth
development successfully completed since the year ended 30 September 2007.
The total property portfolio now comprises 45 properties of which five are under
construction throughout the UK.
End
For further information please contact:
MedicX Fund +44 (0) 1481 723 450
Jorge Tavares, Chairman
MedicX Group +44 (0) 0808 2025461
Keith Maddin, Chairman
Mike Adams, Managing Director
Buchanan Communications +44 (0) 20 7466 5000
Charles Ryland / Mary-Jane Johnson
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.